Improving skills in pediatric rheumatology in Colombia: a combined educational strategy supported by ILAR.

Colombia is a densely populated country with a small number of pediatric rheumatology specialists, including 14 specialists for a population of 1,927,000 children in 2014. The objective of the study was to improve the skills required for early identification, timely referral, and management of musculoskeletal diseases, especially juvenile idiopathic arthritis (JIA), in a group of pediatricians and pediatric residents in a remote region of Colombia. Supported by grant programs developed by the International League of Associations for Rheumatology (ILAR), a combined educational strategy (blended learning) was implemented based on two classroom educational activities and four online modules. The students' acquired knowledge and perception of the strategy were evaluated. Scores were reported as median values and interquartile ranges (IQR), and the differences between scores were estimated using the Wilcoxon test for equal medians. Forty-one students were enrolled, 37 completed the online modules, and 33 attended the final in-person session. The results of the written tests demonstrated an improved ability to solve clinical problems compared with the results of the tests before the course (the median initial vs. final test scores 3 (IQR = 1) vs. 5 (IQR = 0), p = 0.000). The students reported high levels of satisfaction related to compliance with the proposed objectives, the relevance of the contents and activities performed, and the impact on everyday practice. These types of strategies are useful as tools for continuing medical education. However, the results pertain only to short-term learning. It is necessary to evaluate their impact on "lifelong learning."

Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study.

OBJECTIVE: To determine the frequency of selected serum autoantibodies and their clinical associations in patients with childhood-onset (ChO) or adult-onset (AO) linear scleroderma (LiScl) evaluated at a single institution. METHODS: Seventy-two patients (ChO = 40, AO = 32), including 12 with en coup de sabre, were studied. All ChO patients had disease onset before age 16 years. Clinical features (extent of cutaneous disease, activity, and joint contractures) were recorded. Antinuclear antibodies (ANA) were identified by indirect immunofluorescence (HEp-2 cells), and anti-single-stranded DNA (anti-ssDNA), antihistone (AHA), and antichromatin (AChA) autoantibodies were detected by ELISA. RESULTS: There were no significant differences between groups in regard to gender, proportion with LiScl/E, or clinical features except joint contractures (ChO > AO; p = 0.04). There were no differences in the frequency of ANA or other autoantibodies between the groups except for AHA (ChO > AO). AHA was more frequently found with anti-ssDNA (p < 0.0001). LiScl patients with positive anti-ssDNA and/or AHA had more extensive cutaneous involvement and more often had joint contractures (p < 0.05). Anti-ssDNA was present more frequently in AO than in ChO patients with active lesions (p = 0.04). ANA and AChA were not associated with any clinical features. Both AHA and anti-ssDNA levels showed good correlation with disease severity. CONCLUSION: Over two-thirds of LiScl patients had ANA. Patients with ChO were similar to those with AO with regard to the frequency of selected serum autoantibodies. Anti-ssDNA and AHA were frequently found together and both were associated with more extensive skin disease with joint contractures. LiScl disease severity correlated with the serum levels of both these antibodies.

Localized scleroderma severity index and global assessments: a pilot study of outcome instruments.

OBJECTIVE: To develop a disease outcome instrument measuring localized scleroderma (LS) severity and to determine its reliability. METHODS: Patients with LS were evaluated by 2 rheumatologists. The LS Severity Index (LoSSI) comprises the sum of 4 clinical skin scores measured at 14 cutaneous anatomic sites: extent of surface area (SA) affected, erythema score (ES), skin thickness (ST) score, and new lesion/extension (N/E). Physician and patient global assessments (GA) were recorded on a 100 mm visual analog scale. RESULTS: Twenty-two patients with LS had 66 visits, during which 91 lesions were assessed. Individual skin scores (SA, ES, ST) and LoSSI showed substantial interrater reliability (kappaw 0.77-0.83; percentage agreement 93.41%-96.70%). Intrarater variability was calculated using 26 anatomic sites and 9 pair-visits. Each skin score demonstrated excellent reliability (kappaw 0.56-0.80, percentage agreement 90.39%-94.23%). Physician GA showed substantial interrater correlation [0.72, 95% confidence interval (CI) 0.57, 0.87]. There was only fair correlation between physician and patient GA (0.27, 95% CI 0.00, 0.64). The standardized response means for LoSSI and physician GA were large (1.86 and 2.55) for those who improved after therapy. CONCLUSION: LS clinical trials are impeded by the lack of reliable and reproducible outcome measures. We have developed the LoSSI to correct this deficiency. Our pilot study demonstrates that the LoSSI is reliable and reproducible in measuring LS severity and therapeutic effects and can be easily implemented into the clinical examination of patients with LS. Both LoSSI and physician GA were sensitive to clinical changes in patients with LS. A formal study should be conducted to validate these preliminary findings.